Loading stock…

AstraZeneca PLC (AZN) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

AZNAstraZeneca

Revenue FY25$58.7B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+57%9

EPS growth, FY27E+11%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

AZNAstraZeneca

Total return Current275%

Price return Current195%

MOMENTUM RATING↗

AVERAGE44 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-6%5

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-5%4

3-year return+16%4

5-year return+50%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

Average long-term results. Multi-year returns are middling (+16% over three years and +50% over five), roughly average for the market.

It's down 5% over the past year, now 22% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on AstraZeneca. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AZNAstraZeneca

Revenue FY25$58.7B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+57%9

EPS growth, FY27E+11%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

AZNAstraZeneca

Total return Current275%

Price return Current195%

MOMENTUM RATING↗

AVERAGE44 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-6%5

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-5%4

3-year return+16%4

5-year return+50%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

Average long-term results. Multi-year returns are middling (+16% over three years and +50% over five), roughly average for the market.

It's down 5% over the past year, now 22% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on AstraZeneca. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

AstraZeneca PLC

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on AstraZeneca. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on AstraZeneca. Get the full investment case.

Premium